These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 37160786)
81. Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. Smits MM; Fluitman KS; Herrema H; Davids M; Kramer MHH; Groen AK; Belzer C; de Vos WM; Cahen DL; Nieuwdorp M; van Raalte DH Diabetes Metab; 2021 Sep; 47(5):101223. PubMed ID: 33429063 [TBL] [Abstract][Full Text] [Related]
82. Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. Liu D; Pang J; Shao W; Gu J; Zeng Y; He HH; Ling W; Qian X; Jin T Hepatology; 2021 Oct; 74(4):2154-2169. PubMed ID: 33851458 [TBL] [Abstract][Full Text] [Related]
83. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Jacobsen LV; Flint A; Olsen AK; Ingwersen SH Clin Pharmacokinet; 2016 Jun; 55(6):657-72. PubMed ID: 26597252 [TBL] [Abstract][Full Text] [Related]
84. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100 [TBL] [Abstract][Full Text] [Related]
85. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice. van Velsen EF; Lamers J; Blok V; van Leendert RJ; Kiewiet-Kemper RM Neth J Med; 2014 Dec; 72(10):523-7. PubMed ID: 26219757 [TBL] [Abstract][Full Text] [Related]
86. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Vadini F; Simeone PG; Boccatonda A; Guagnano MT; Liani R; Tripaldi R; Di Castelnuovo A; Cipollone F; Consoli A; Santilli F Int J Obes (Lond); 2020 Jun; 44(6):1254-1263. PubMed ID: 31965072 [TBL] [Abstract][Full Text] [Related]
87. A GLP-1/glucagon (GCG)/CCK Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823 [TBL] [Abstract][Full Text] [Related]
88. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244 [TBL] [Abstract][Full Text] [Related]
89. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. Ng NBH; Low YW; Rajgor DD; Low JM; Lim YY; Loke KY; Lee YS Clin Endocrinol (Oxf); 2022 Feb; 96(2):144-154. PubMed ID: 34448208 [TBL] [Abstract][Full Text] [Related]
90. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related]
91. Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. Keskin L; Yaprak B Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6813-6820. PubMed ID: 36196729 [TBL] [Abstract][Full Text] [Related]
93. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice. Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235 [TBL] [Abstract][Full Text] [Related]
94. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597 [TBL] [Abstract][Full Text] [Related]
95. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314 [No Abstract] [Full Text] [Related]
96. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Hogan AE; Tobin AM; Ahern T; Corrigan MA; Gaoatswe G; Jackson R; O'Reilly V; Lynch L; Doherty DG; Moynagh PN; Kirby B; O'Connell J; O'Shea D Diabetologia; 2011 Nov; 54(11):2745-54. PubMed ID: 21744074 [TBL] [Abstract][Full Text] [Related]
97. Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial. Bensignor MO; Bramante CT; Bomberg EM; Fox CK; Hale PM; Kelly AS; Mamadi R; Prabhu N; Harder-Lauridsen NM; Gross AC Pediatr Obes; 2023 Sep; 18(9):e13061. PubMed ID: 37264767 [TBL] [Abstract][Full Text] [Related]
98. Single-Center Experience of Using Liraglutide in Adolescents With Obesity +/- Type 2 Diabetes. Dauleh H; Pasha M; Gad H; Haris B; Petrovski G; Afyouni H; Khalifa A; Shehzad S; Amin R; Chirayath S; Mohamadsalih G; Mohammed S; Malik RA; Hussain K Cureus; 2024 Apr; 16(4):e58720. PubMed ID: 38779269 [TBL] [Abstract][Full Text] [Related]
99. Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease. Zhang Z; Qi Y; Kong W; Jin Q; Wang X; Dong Y; Wang Y; Li H Med Sci Monit; 2018 Oct; 24():7399-7404. PubMed ID: 30325900 [TBL] [Abstract][Full Text] [Related]